PubRank

Jan Fehr

Author PubWeight™ 23.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr 2013 3.02
2 Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 2013 1.90
3 Close geographic association of human neoehrlichiosis and tick populations carrying "Candidatus Neoehrlichia mikurensis" in eastern Switzerland. J Clin Microbiol 2012 1.14
4 Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 2011 1.10
5 Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012 1.09
6 HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. PLoS Genet 2013 1.04
7 Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther 2009 1.03
8 Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PLoS One 2012 0.91
9 High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. Clin Infect Dis 2009 0.90
10 Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008 0.87
11 Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis 2011 0.87
12 Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr 2013 0.84
13 Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014 0.83
14 Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation. PLoS One 2012 0.83
15 Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clin Infect Dis 2015 0.83
16 Benefit of a single preoperative dose of antibiotics in a sub-saharan district hospital: minimal input, massive impact. Ann Surg 2009 0.82
17 Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS 2015 0.82
18 "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infect Dis 2014 0.78
19 Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. J Acquir Immune Defic Syndr 2015 0.78
20 The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. J Acquir Immune Defic Syndr 2016 0.76
21 Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS 2015 0.76
22 Reply: To PMID 23892243. J Acquir Immune Defic Syndr 2014 0.75
23 Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. Medicine (Baltimore) 2016 0.75
24 An unusual presentation of amebic liver abscesses. CMAJ 2010 0.75
25 Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2013 0.75
26 [Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]. Pflege 2005 0.75
27 [Limitations of medicine:diagnosis and therapy of <<inflammatory>> back pain]. Praxis (Bern 1994) 2014 0.75